MG
Recent EQ News
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/15/2024 02:50:36 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2024 09:05:08 PM
- Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates • Business Wire • 11/13/2024 09:01:00 PM
- Equillium to Present at the Stifel Healthcare Conference • Business Wire • 11/13/2024 01:00:00 PM
- Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer • Business Wire • 11/12/2024 01:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 10/31/2024 04:19:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2024 11:05:36 AM
- Equillium Maintains Rights to Itolizumab Following Ono Partnership • Business Wire • 10/31/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 12:59:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/29/2024 08:15:06 PM
- Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer • Business Wire • 10/07/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/17/2024 10:14:15 PM
- Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit • Business Wire • 09/10/2024 12:00:00 PM
- Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 09/04/2024 12:00:00 PM
- Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference • Business Wire • 08/28/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:10:26 PM
- Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights • Business Wire • 08/08/2024 08:01:00 PM
- Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease • Business Wire • 08/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 08:01:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 06:08:53 PM
- Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance • Business Wire • 07/18/2024 05:57:00 PM
- Equillium to Participate in Upcoming Investor Conferences • Business Wire • 07/02/2024 12:00:00 PM
- Equillium to be included in the Russell Microcap® Index • Business Wire • 06/12/2024 12:00:00 PM
- Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 06/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 12:00:55 PM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM